Does the media favor ACAD or SVRA?

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Savara. MarketBeat recorded 8 mentions for ACADIA Pharmaceuticals and 7 mentions for Savara. Savara's average media sentiment score of 1.24 beat ACADIA Pharmaceuticals' score of 1.11 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LEGN or SVRA more profitable?

Savara has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Legend Biotech's return on equity of -24.92% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% Savara N/A -87.19% -66.42%

Does the media favor LEGN or SVRA?

In the previous week, Legend Biotech had 5 more articles in the media than Savara. MarketBeat recorded 12 mentions for Legend Biotech and 7 mentions for Savara. Savara's average media sentiment score of 1.24 beat Legend Biotech's score of 0.43 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, SVRA or VKTX?

Savara is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Viking Therapeutics N/A N/A -$359.64M -$4.14 N/A

Is SVRA or VKTX more profitable?

Viking Therapeutics' return on equity of -71.31% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% Viking Therapeutics N/A -71.31% -65.35%

Does the media prefer SVRA or VKTX?

In the previous week, Viking Therapeutics had 12 more articles in the media than Savara. MarketBeat recorded 19 mentions for Viking Therapeutics and 7 mentions for Savara. Savara's average media sentiment score of 1.24 beat Viking Therapeutics' score of 0.64 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, SVRA or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.66 N/A

Is SVRA or EWTX more profitable?

Edgewise Therapeutics' return on equity of -32.55% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% Edgewise Therapeutics N/A -32.55% -31.04%

Does the media prefer SVRA or EWTX?

In the previous week, Savara had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 7 mentions for Savara and 6 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.72 beat Savara's score of 1.24 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is TNGX or SVRA more profitable?

Tango Therapeutics' return on equity of -41.54% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -41.54% -33.44% Savara N/A -87.19% -66.42%

Does the media prefer TNGX or SVRA?

In the previous week, Savara had 4 more articles in the media than Tango Therapeutics. MarketBeat recorded 7 mentions for Savara and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.24 beat Savara's score of 1.24 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Savara (SVRA) Competitors

$5.33 -0.10 (-1.84%)

Closing price 07/28/2026 04:00 PM Eastern

Extended Trading

$5.34 +0.00 (+0.09%)

As of 07/28/2026 04:10 PM Eastern

Compare

SVRA vs. ACAD, LEGN, VKTX, EWTX, and TNGX

Should you buy Savara stock or one of its competitors? MarketBeat compares Savara with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Savara include ACADIA Pharmaceuticals (ACAD), Legend Biotech (LEGN), Viking Therapeutics (VKTX), Edgewise Therapeutics (EWTX), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.

How does Savara compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Savara (NASDAQ:SVRA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Savara. MarketBeat recorded 8 mentions for ACADIA Pharmaceuticals and 7 mentions for Savara. Savara's average media sentiment score of 1.24 beat ACADIA Pharmaceuticals' score of 1.11 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals presently has a consensus target price of $33.17, indicating a potential upside of 27.52%. Savara has a consensus target price of $10.14, indicating a potential upside of 90.30%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.67
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

ACADIA Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Savara has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Savara's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Savara	N/A	-87.19%	-66.42%

ACADIA Pharmaceuticals has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.16	$391M	$2.20	11.82
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Summary

ACADIA Pharmaceuticals beats Savara on 12 of the 16 factors compared between the two stocks.

How does Savara compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Savara (NASDAQ:SVRA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Savara has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.44	-$296.80M	-$0.68	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Legend Biotech presently has a consensus target price of $55.29, suggesting a potential upside of 190.37%. Savara has a consensus target price of $10.14, suggesting a potential upside of 90.30%. Given Legend Biotech's higher possible upside, equities research analysts clearly believe Legend Biotech is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Legend Biotech had 5 more articles in the media than Savara. MarketBeat recorded 12 mentions for Legend Biotech and 7 mentions for Savara. Savara's average media sentiment score of 1.24 beat Legend Biotech's score of 0.43 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Legend Biotech has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Savara has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Savara has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Legend Biotech's return on equity of -24.92% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Savara	N/A	-87.19%	-66.42%

Summary

Savara beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Savara compare to Viking Therapeutics?

Savara (NASDAQ:SVRA) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Viking Therapeutics had 12 more articles in the media than Savara. MarketBeat recorded 19 mentions for Viking Therapeutics and 7 mentions for Savara. Savara's average media sentiment score of 1.24 beat Viking Therapeutics' score of 0.64 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	10 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Savara has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Viking Therapeutics' return on equity of -71.31% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Viking Therapeutics	N/A	-71.31%	-65.35%

Savara presently has a consensus price target of $10.14, suggesting a potential upside of 90.30%. Viking Therapeutics has a consensus price target of $97.00, suggesting a potential upside of 186.47%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

87.9% of Savara shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Viking Therapeutics beats Savara on 7 of the 12 factors compared between the two stocks.

How does Savara compare to Edgewise Therapeutics?

Savara (NASDAQ:SVRA) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Savara has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

87.9% of Savara shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Savara currently has a consensus price target of $10.14, indicating a potential upside of 90.30%. Edgewise Therapeutics has a consensus price target of $48.75, indicating a potential upside of 20.82%. Given Savara's stronger consensus rating and higher possible upside, equities research analysts clearly believe Savara is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Edgewise Therapeutics' return on equity of -32.55% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

In the previous week, Savara had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 7 mentions for Savara and 6 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.72 beat Savara's score of 1.24 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Savara beats Edgewise Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Savara compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Savara (NASDAQ:SVRA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Tango Therapeutics presently has a consensus target price of $42.15, indicating a potential upside of 58.18%. Savara has a consensus target price of $10.14, indicating a potential upside of 90.30%. Given Savara's stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Savara had 4 more articles in the media than Tango Therapeutics. MarketBeat recorded 7 mentions for Savara and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.24 beat Savara's score of 1.24 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Savara has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Tango Therapeutics' return on equity of -41.54% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Savara	N/A	-87.19%	-66.42%

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tango Therapeutics has higher revenue and earnings than Savara. Tango Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	61.80	-$101.59M	-$0.83	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Summary

Tango Therapeutics beats Savara on 8 of the 15 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVRA vs. The Competition

Export

Metric	Savara	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.11B	$3.05B	$7.08B	$12.19B
Dividend Yield	N/A	2.06%	2.66%	8.55%
P/E Ratio	-9.52	20.47	27.27	23.75
Price / Sales	N/A	799.56	578.56	109.45
Price / Cash	N/A	27.27	49.60	59.05
Price / Book	5.33	4.09	10.11	6.06
Net Income	-$118.84M	$67.27M	$3.60B	$336.44M
7 Day Performance	-5.66%	-3.34%	-0.95%	-1.50%
1 Month Performance	-11.61%	-7.64%	-3.59%	-4.62%
1 Year Performance	103.44%	12.49%	20.53%	15.02%

Savara Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVRA Savara	2.0668 of 5 stars	$5.33 -1.8%	$10.14 +90.3%	+100.4%	$1.11B	N/A	N/A	20	News Coverage Positive News Gap Up
ACAD ACADIA Pharmaceuticals	4.6409 of 5 stars	$25.19 +0.4%	$33.17 +31.7%	+15.0%	$4.31B	$1.07B	11.44	510	Positive News Upcoming Earnings
LEGN Legend Biotech	3.1603 of 5 stars	$23.23 +0.1%	$57.00 +145.4%	-54.1%	$4.31B	$1.03B	N/A	2,965	News Coverage Analyst Forecast
VKTX Viking Therapeutics	3.4344 of 5 stars	$37.09 +1.9%	$93.60 +152.4%	+2.0%	$4.30B	N/A	N/A	20	News Coverage
EWTX Edgewise Therapeutics	3.554 of 5 stars	$39.49 -0.7%	$48.75 +23.5%	+183.0%	$4.24B	N/A	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVRA) was last updated on 7/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Savara (SVRA) Competitors

SVRA vs. ACAD, LEGN, VKTX, EWTX, and TNGX

How does Savara compare to ACADIA Pharmaceuticals?

Summary

How does Savara compare to Legend Biotech?

Summary

How does Savara compare to Viking Therapeutics?

Summary

How does Savara compare to Edgewise Therapeutics?

Summary

How does Savara compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Savara (SVRA) Competitors

SVRA vs. ACAD, LEGN, VKTX, EWTX, and TNGX

How does Savara compare to ACADIA Pharmaceuticals?

Do insiders & institutionals have more ownership in ACAD or SVRA?

Does the media favor ACAD or SVRA?

Do analysts prefer ACAD or SVRA?

Which has more risk and volatility, ACAD or SVRA?

Is ACAD or SVRA more profitable?

Which has preferable earnings and valuation, ACAD or SVRA?

Summary

How does Savara compare to Legend Biotech?

Which has better earnings and valuation, LEGN or SVRA?

Do analysts prefer LEGN or SVRA?

Does the media favor LEGN or SVRA?

Do insiders and institutionals hold more shares of LEGN or SVRA?

Which has more risk & volatility, LEGN or SVRA?

Is LEGN or SVRA more profitable?

Summary

How does Savara compare to Viking Therapeutics?

Does the media prefer SVRA or VKTX?

Which has stronger earnings and valuation, SVRA or VKTX?

Which has more volatility & risk, SVRA or VKTX?

Is SVRA or VKTX more profitable?

Do analysts prefer SVRA or VKTX?

Do insiders & institutionals have more ownership in SVRA or VKTX?

Summary

How does Savara compare to Edgewise Therapeutics?

Which has more volatility and risk, SVRA or EWTX?

Do insiders and institutionals believe in SVRA or EWTX?

Do analysts rate SVRA or EWTX?

Is SVRA or EWTX more profitable?

Which has higher earnings and valuation, SVRA or EWTX?

Does the media prefer SVRA or EWTX?

Summary

How does Savara compare to Tango Therapeutics?

Do analysts rate TNGX or SVRA?

Does the media prefer TNGX or SVRA?

Which has more volatility & risk, TNGX or SVRA?

Is TNGX or SVRA more profitable?

Do insiders & institutionals believe in TNGX or SVRA?

Which has preferable valuation and earnings, TNGX or SVRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools